Search Login Register

Thalassemia Summary

Description: A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.

Also Known As: Thalassemias

Networked: 3420 relevant articles (151 outcomes, 382 trials/studies) for this Disease

Key Drugs and Agents for Thalassemia

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Iron : 32 outcomes 65 studies in 565 results : IBA
  2. Globins : 18 outcomes 66 studies in 499 results : IBA
  3. Hemoglobins (Hemoglobin) : 10 outcomes 45 studies in 571 results : IBA
  4. deferasirox : 10 outcomes 17 studies in 49 results : FDA 1
  5. deferiprone (CP20) : 10 outcomes 9 studies in 61 results : IBA
  6. Deferoxamine (Desferal) : 10 outcomes 8 studies in 92 results : FDA 5 Generic
  7. Fetal Hemoglobin (Hemoglobin F) : 7 outcomes 10 studies in 181 results : IBA
  8. Hydroxyurea (Hydrea) : 5 outcomes 6 studies in 40 results : FDA 6 Generic
  9. Chelating Agents : 4 outcomes 5 studies in 35 results : IBA
  10. DNA (Deoxyribonucleic Acid) : 3 outcomes 8 studies in 173 results : IBA
Show All >>

Diseases Related to Thalassemia

  1. Sickle Cell Anemia (Hemoglobin S Disease)
  2. Iron Overload
  3. Anemia
  4. beta-Thalassemia (Cooley's Anemia)
  5. Osteoporosis
Show All >>

Key Therapies for Thalassemia

Efficacy Chart >>
  1. Bone Marrow Transplantation (Transplantation, Bone Marrow) : 8 outcomes 5 studies in 121 results
  2. Transplants (Transplant) : 8 outcomes 3 studies in 74 results
  3. Chelation Therapy (Therapy, Chelation) : 7 outcomes 8 studies in 95 results
  4. Transplantation (Transplant Recipients) : 6 outcomes 3 studies in 80 results
  5. Blood Transfusion (Blood Transfusions) : 4 outcomes 17 studies in 146 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.